Tokyo Tape
Sign in
← OncoTherapy Science

Quarterly report · Q1

4564.TEDINET S100ROVK
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 30
MetricValuePeriodScopeSource row
Revenue¥148m2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥386m2022-04-01 → 2022-06-30Cons.Net sales
Operating income−¥386m2023-04-01 → 2023-06-30Cons.Operating income
Operating income−¥307m2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income−¥397m2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income−¥1.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥314m2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax−¥400m2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax−¥277m2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)−¥400m2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.1bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥278m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income−¥400m2023-04-01 → 2023-06-30Cons.Profit loss
Net income−¥278m2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥1.3bnat 2023-06-30Cons.Assets
Total assets¥1.5bnat 2023-03-31Cons.Assets
Total assets¥2.0bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥346mat 2023-06-30Cons.Liabilities
Total liabilities¥656mat 2023-03-31Cons.Liabilities
Net assets / equity¥930mat 2023-06-30Cons.Net assets
Net assets / equity¥855mat 2023-03-31Cons.Net assets
Net assets / equity¥1.7bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥913mat 2023-06-30Cons.Cash and deposits
Cash and deposits¥1.1bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥-1.992023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-5.812022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.442022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio66.5%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio51.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio79.3%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥122,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥122,000
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥102m
jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥148m
jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥148m
jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2023-04-01 → 2023-06-30−¥51m
jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2023-04-01 → 2023-06-30¥509,000
jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2023-04-01 → 2023-06-30¥387,000
jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥122,000
jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2023-04-01 → 2023-06-30−¥233m
—segment totalrevenue2023-04-01 → 2023-06-30¥148m
—segment totalrevenue external2023-04-01 → 2023-06-30¥148m
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥122,000
—segment totalsegment profit2023-04-01 → 2023-06-30−¥284m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥55,000
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥55,000
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥101m
jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥380m
jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥380m
jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥9m
jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2022-04-01 → 2022-06-30¥6m
jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2022-04-01 → 2022-06-30¥6m
jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥55,000
jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2022-04-01 → 2022-06-30−¥215m
—segment totalrevenue2022-04-01 → 2022-06-30¥386m
—segment totalrevenue external2022-04-01 → 2022-06-30¥386m
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥55,000
—segment totalsegment profit2022-04-01 → 2022-06-30−¥206m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 300
ItemContextValueUnit
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-122000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember509000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember147749000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember148259000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-122000JPY
Net salesCurrentYTDDuration148137000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember-232590000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember-51211000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember-283801000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember-102450000JPY
Operating incomeCurrentYTDDuration-386251000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-08-14
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第23期第１四半期（自　2023年４月１日　至　2023年６月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)オンコセラピー・サイエンス株式会社
Company name in english cover pageFilingDateInstantOncoTherapy Science, Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　嶋田　順一
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)神奈川県川崎市川崎区東田町１番地２
Telephone number address of registered headquarter cover pageFilingDateInstant044－201－6429
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)管理本部長　水越　潤一
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)神奈川県川崎市川崎区東田町１番地２
Telephone number nearest place of contact cover pageFilingDateInstant044－201－6429
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)管理本部長　水越　潤一
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE05363
Fund codeFilingDateInstant－
Security codeFilingDateInstant45640
Filer name in japaneseFilingDateInstant
Original text (Japanese)オンコセラピー・サイエンス株式会社
Filer name in englishFilingDateInstantOncoTherapy Science, Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Current fiscal year start dateFilingDateInstant2023-04-01
Current period end dateFilingDateInstant2023-06-30
Type of current periodFilingDateInstantQ1
Current fiscal year end dateFilingDateInstant2024-03-31
Previous fiscal year start dateFilingDateInstant2022-04-01
Comparative period end dateFilingDateInstant2022-06-30
Previous fiscal year end dateFilingDateInstant2023-03-31
Next fiscal year start dateFilingDateInstant－
End date of quarterly or semi annual period of next fiscal yearFilingDateInstant－
Amendment flagFilingDateInstantfalse

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass